Epacadostat
Malignant Ovarian Clear Cell Tumor
National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Malignant Ovarian Clear Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab National Cancer Institute (NCI) | Phase 2 | B |
Sargramostim Barbara Ann Karmanos Cancer Institute | Phase 1 | CC |
her2bi-armed activated t cells Barbara Ann Karmanos Cancer Institute | Phase 1 | C |
Same molecule, other indications
Epacadostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →